デイリーニュース

Yuhan Corp. participated in 2026 university job fairs at Seoul National, Sungkyunkwan and Ewha, presenting R&D, production and regulatory roles to attract top pharma‑bio talent.

Korea AbbVie received the 2026 Global Open Innovation Activation Contribution Award from the Ministry of Health and Welfare for supporting domestic biotech firms' global expansion and tech collaboration.

Yuyu Pharmaceutical CEO Yoo Won-sang, the third‑generation owner, has launched the "Robert’s YUniverse" podcast, featuring global experts across pharma, animal health, K‑culture and more.

Korean Lily was honored with the 2026 Open Innovation Activation Award (group category) by the Korea Health Industry Development Institute at the Global Open Innovation Week – Biohealth in Seoul.

Celltrion announced a partnership with Japan’s Kobe Biomedical Innovation Cluster, launching the 2026 KBIC‑Celltrion Global Scale‑up Program to help promising biotech startups expand globally.

ARKGEN BioScions announced a 10 billion KRW Series A round, raising total funding to 14 billion KRW to accelerate development of next‑generation multi‑antibody immuno‑oncology drugs.

TriOne Co. was chosen for a Ministry of SMEs and Startups joint public‑private R&D project to advance Ph-30, a first‑in‑class chiral gamma‑lactam that inhibits both MAO‑B and myostatin for Parkinson’s disease and muscle targets.

GC Cell signed an MOU with Excel Therapeutics, CoaStem ChemOn, Jin Medisin and GCCL to create a CGT Value Chain Alliance, fostering cooperation across the cell and gene therapy sector in Korea.

LG Chem signed a strategic collaboration with Chinese biotech OTR Therapeutics to discover and develop promising oncology drug candidates, leveraging China’s biotech ecosystem.

Plus Therapeutics has changed its name to Cerenome, reflecting an expanded business focus.

Hanmi Pharmaceutical and Kiwoom Securities announced they will hold a Bio Innovation Day on June 15 in Seoul to connect biotech ventures with investors and boost the domestic bio‑venture ecosystem.

Novartis announced an $1.1 billion upfront payment to acquire London‑based Myricx Bio, aiming to add a novel payload‑based ADC pipeline to its oncology portfolio.